Staff Reports
The Pentagon quietly pulled down a new clinical guidance it had posted that would have added routine testosterone screening for service members aged 30 and older. The directive, pushed publicly by Secretary of Defense Pete Hegseth as part of a drive for greater “warfighter” readiness, was posted and then rescinded while the department updates the language. It’s a good idea to care about troop health — but the way this was rolled out raises real questions.
What the draft guidance would have done
The draft guidance would have added a testosterone-deficiency screening to the annual health check for troops 30 and up. Men under 30 could opt in. The plan included a short questionnaire that might lead to a blood test and, if low levels were confirmed, the option of hormone therapy. Women would not get routine blood tests under the draft, but would answer questions about menstrual cycles. The Pentagon says the guidance is being updated and a final version will appear soon.
Why conservatives should applaud the goal — and worry about the rollout
Secretary of Defense Pete Hegseth is right to focus on readiness and preserving the long-term health of troops. A fit, healthy force matters. But good intentions are not a green light for sloppy policy. Publishing a medical directive one day and pulling it the next looks like rush work, not careful medical practice. Doctors and medical societies warn that diagnosing “low T” requires symptoms and repeat early-morning tests, not a single checkbox on a tablet. We should back policies that help soldiers, not ones that risk unnecessary treatments or create medical confusion in the ranks.
Medical caution, consent, and oversight should come first
If the Pentagon wants to test hormones, it must follow established medical standards: clear diagnostic criteria, confirmatory testing, informed consent, and strong clinical oversight. No troop should feel pressured into hormonal treatment to meet some abstract idea of “performance.” Lawmakers and military leaders should demand transparency about protocols, who is covered, how results are handled, and what safeguards exist against overtreatment. If the goal is readiness, then do it right — not with a headline-first, document-second approach.
Secretary Hegseth’s focus on fighting strength is welcome. The problem is execution. The department can protect troops and improve readiness at the same time, but only if medical science, patient rights, and clear rules lead the way. Pulling the guidance was the right immediate move; the next step should be a careful, well-explained plan that earns the trust of soldiers, doctors, and Congress — not another hurried policy stunt that gets yanked off the web before anyone can read it.
